Transition Therapeutics – About the Company
Transition’s lead product candidate for CNS diseases, ELND005, is being developed for the treatment of agitation and aggression in Alzheimer’s disease patients and Down syndrome. A large Phase II clinical trial enrolling approximately 400 AD patients is in progress and the Phase IIa trial for Down syndrome is near completion. The ELND005 asset is un-partnered since Transition acquired all the development and commercialization rights from Perrigo Company plc.
Complementing this late-stage development asset, the Company has a core business model whereby promising development projects are in-licensed from large pharmaceutical companies. Transition develops the project through a pre-specified stage of development, and then the larger company usually has an exclusive option to perform late stage, pivotal clinical trials. The larger company is then also responsible for commercialization and marketing of the drug, while Transition receives milestone payments and royalties. Transition shares trade on exchanges in both the US (NASDAQ: TTHI) and Canada (TSX: TTH).
Transition’s core business model yielded lead metabolic drug candidate is TT401, a GLP-1 dual agonist licensed from Eli Lilly (NYSE:LLY) for the treatment of type 2 diabetes and accompanying obesity. The Company seeks to continue expanding its development pipeline with the addition of new in-licensed programs under similar arrangements as the TT401 collaboration agreement.